The effect of apigenin on CRC occurs by inhibiting the PI3K/Akt/mTOR pathway, which is considered an important therapeutic target due to its abnormal activation in many cancers (Sain, Kandasamy, and Naskar 2022). This evidence concerns the gene AKT1 and cancer.